
Oncotelic Therapeutics Featured in Analysis of Biotech Valuation Trends
Oncotelic Therapeutics is preparing for a significant fair-value remeasurement of its 45% stake in joint venture GMP Bio following an independent valuation that suggests potential asset value appreciation, highlighting how GAAP accounting measures are becoming key indicators of scientific and commercial progress in late-stage biotech companies.
Read full story

























